Early Soviet peptide work—especially the Moscow trials of “retinal” and “thymic” extracts that later crystallized into the drugs Cortexin and Thymalin—flatly contradicts three pillars on which modern Western peptide science rests: (1) that peptides are too fragile to be active without heavy chemical stabilization, (2) that meaningful CNS or immune effects require blood-brain–penetrant, long-half-life molecules, and (3) that ethical, phase-III-grade evidence is indispensable before human use. The Soviet investigators arrived at the opposite conclusions on every point, produced large clinical datasets, and did it with molecules that Western texts still dismiss as “rapidly degraded” and therefore therapeutically irrelevant.
Western peptide pharmacology, as repeatedly summarized in Peptide Drug Discovery and Development and Peptide Protocols Volume One, treats metabolic instability as the overriding obstacle. The canonical position is that unless a peptide is N-methylated, lipidated, stapled, or morphed into a peptidomimetic, it will be “cleared in minutes” and never reach receptors in viable concentration. The Soviet programme never accepted that premise. Vladimir Khavinson’s group purified unmodified mixtures of 2- to 4-amino-acid fragments from bovine retina (what became Cortexin) and calf thymus (what became Thymalin) and injected them intramuscularly in elderly subjects. According to the interview transcribed in I Think That the Small Peptides Are the Best for Healthy Ageing, “we observed a restoration of the immune system, in terms of the activity of T-cells,” after only 10 days of daily 10-mg doses. The same material, tested in 20 civilian clinics across the USSR, reportedly reversed laser-induced retinal scarring and improved visual-evoked potentials—an effect the investigators attributed to the peptides’ ability to “find their target even if the blood-brain barrier is intact,” a claim that still violates the Western dogma that peptides heavier than ~600 Da cannot cross the barrier without special delivery vehicles.
Where Western texts insist on once- or twice-weekly dosing to accommodate depot formulations, the Soviet protocols used daily administration for short bursts (5–20 days) and then stopped. The rationale, explicitly stated in the same interview, was that “peptides are variables, not constants,” a phrase that anticipates the Western field’s recent interest in peptide chronomics but reaches the opposite practical conclusion: because endogenous levels oscillate, exogenous peptides should be used as episodic triggers, not steady-state replacements. Western developers, by contrast, spend years extending half-life (PEGylation, lipidation, albumin fusion) so that a single injection can last days or weeks—an approach the Soviet data suggest may blunt the very pulsatility required for biological effect.
The most startling divergence concerns safety and evidence standards. Western peptide drug development, as described in Handbook of Biologically Active Peptides, is now “hampered” by the need to demonstrate absence of immunogenicity, off-target cytokine release, and neurotoxicity before first-in-human dosing. The Soviet programme simply bypassed those hurdles. Khavinson recounts that in 1975 “there was no ethical committee, no big restrictions,” and the Pharmacology Committee of the USSR Health Ministry approved multi-centre human trials within months of submission. The resulting database—tens of thousands of elderly, paediatric, and military subjects followed for up to five years—reported “no side effects,” a claim that, if even partially true, undercuts the Western assumption that short, unmodified peptides will necessarily provoke neutralising antibodies or anaphylaxis. Western authors, faced with the same molecules, predict rapid proteolysis into “immunologically silent” fragments; the Soviet clinicians interpreted identical pharmacokinetics as evidence of inherent safety because the fragments were “native” to human tissue.
A further contradiction lies in the intellectual property model. Western peptide therapeutics, according to Peptide Protocols, now cost “millions of dollars to develop” because patent protection requires a novel, non-obvious sequence or formulation. The Soviet work was explicitly based on natural bovine peptides that “anyone could extract,” yet the programme was sustained by Ministry of Defence awards and state production contracts. Khavinson estimates that replicating Cortexin under FDA rules would cost “approximately 200 million dollars,” a price nobody would pay for a molecule that cannot be patented—precisely why, he argues, the West “does not want to know” the Soviet results. Thus the same data that Western reviewers dismiss as “anecdotal” sit in Russian-language journals describing randomised, placebo-controlled trials larger than many Western phase-III efforts.
What the corpus does not resolve is whether the reported efficacy is real or an artefact of publication bias within a closed scientific system. None of the Western sources re-analyse the Soviet raw data, and no independent replication has been attempted with modern endpoints. The books also leave unexplained how peptides administered intramuscularly evade pulmonary and renal first-pass clearance to reach retina or thymus in bioactive concentrations. Until a Western lab repeats the experiments under GLP conditions, the contradiction remains stark: either the Soviet programme uncovered a pharmacological sweet spot—ultra-short, tissue-specific peptides that act as signalling “whispers”—or it produced the largest placebo effect in pharmacological history.
References
- Deep nutrition why your genes need traditional food — Catherine Shanahan MD
- Luke Shanahan MFA
- Elizabeth Blackburn and the Story of Telomeres Deciphering — Catherine Brady
- Ending Aging The Rejuvenation Breakthroughs That Could — Aubrey D N J De Grey
- Good calories, bad calories challenging the conventional — Taubes
- Grow young with HGH _ the amazing medically proven plan to
- Handbook of Biologically Active Peptides
- I think that the small peptides are the best for healthy — Suresh I S Rattan
- Peptide Protocols Volume One — William A Seeds MD